Studies have reported that EPO treatment decreases the incidence and severity of experimental NEC in animal models [9–11], and a retrospective analysis showed that rhEPO (200 IU/kg intravenously with continuous infusion for 2 weeks starting on the first day of life, or 400 IU/kg subcutaneously three times a week) protected against NEC in very low birth weight infants [12]. Here, EPO is linked to necrotizing enterocolitis.